SCHEMBL12309

SCHEMBL12309

CCc1nc(C)no1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL3447928 0.97
SCHEMBL253675 0.77
SCHEMBL6112332 0.77
SCHEMBL20271452 0.77
SCHEMBL13593973 0.77
SCHEMBL3256199 0.77
SCHEMBL19062291 0.77
SCHEMBL8128674 0.77
SCHEMBL3512334 0.77
SCHEMBL444623 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240207267-A1 (R)-Glutarimide CRBN Ligands and Methods of Use BEIGENE SWITZERLAND GMBH (CH) 2024-06-27 US disclosed
US-20240025880-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-01-25 US disclosed
US-20240025858-A1 CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHOD OF PREPARATION THEREOF JAZZ PHARMACEUTICALS RESEARCH UK LIMITED (GB) 2024-01-25 US disclosed
US-20240025858-A1 CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHOD OF PREPARATION THEREOF JAZZ PHARMACEUTICALS RESEARCH UK LIMITED (GB) 2024-01-25 US disclosed
WO-2023237504-A1 HSD17B13 INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-12-14 WO disclosed
WO-2023230609-A1 HETEROCYCLIC PAD4 INHIBITORS CELGENE CORPORATION (US) 2023-11-30 WO disclosed
WO-2023220247-A1 LRRK2 INHIBITORS INTERLINE THERAPEUTICS, INC. (US) 2023-11-16 WO disclosed
US-20230285310-A1 COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM ARES CAPITAL CORPORATION, AS AGENT 2023-09-14 US disclosed
EP-4233871-A2 INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL Eli Lilly and Company (US) 2023-08-30 EP disclosed
WO-2023147312-A1 AMPK AGONISTS AND METHODS OF USE THEREOF EVVIA THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
US-20080090818-A1 Triazolopyrazine compounds useful for the treatment of degenerative &amp; inflammatory diseases GALAPAGOS NV (BE) 2008-04-17 US disclosed
US-7335632-B2 Beta-secretase inhibitors and methods of use thereof COMENTIS, INC. (US) 2008-02-26 US disclosed
US-20070287705-A1 Crf Receptor Antagonists and Methods Relating Thereto NEUROCRINE BIOSCIENCES, INC. 2007-12-13 US disclosed
US-20070281943-A1 Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases JANSSEN PHARMACEUTICA N.V. (BE) 2007-12-06 US disclosed
US-20070249655-A1 4-Substituted-1,5-Dihydro-Pyrido[3,2-B]Indol-2-Ones KESTELEYN BART R R 2007-10-25 US disclosed
US-20070249655-A1 4-Substituted-1,5-Dihydro-Pyrido[3,2-B]Indol-2-Ones KESTELEYN BART R R 2007-10-25 US disclosed
US-7276520-B2 Bicyclic piperidine derivatives as melanocortin-4 receptor agonists MERCK & CO., INC. (US) 2007-10-02 US disclosed
WO-2007003965-A1 SUBSTITUTED CYCLOHEXYL DERIVATIVES AS NK-3 RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LIMITED (GB) 2007-01-11 WO disclosed
WO-2004002491-A1 MORPHOLINE AND TETRAHYDROPYRAN DRIVATIVES AND THEIR USE AS CATHEPSIN INHIBITORS AVENTIS PHARMACEUTICALS INC. (US) 2004-01-08 WO disclosed
US-4160829-A ANTIBIOTICS GIST-BROCADES N.V. (NL) 1979-07-10 US disclosed